| Long-term cause-specific mortality in Hodgkin lymphoma patients S de Vries, M Schaapveld, CPM Janus, LA Daniëls, EJ Petersen, ... JNCI: Journal of the National Cancer Institute 113 (6), 760-769, 2021 | 77 | 2021 |
| Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin’s lymphoma WJ Plattel, A van den Berg, L Visser, AM van der Graaf, J Pruim, H Vos, ... haematologica 97 (3), 410, 2012 | 75 | 2012 |
| Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC … MJ Kersten, J Driessen, JM Zijlstra, WJ Plattel, F Morschhauser, ... Haematologica 106 (4), 1129, 2021 | 74 | 2021 |
| Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sG alectin‐1, sCD 163 and sCD 30 with TARC WJ Plattel, ZND Alsada, GW van Imhoff, A Diepstra, A van den Berg, ... British journal of haematology 175 (5), 868-875, 2016 | 60 | 2016 |
| Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin’s lymphoma C Xu, W Plattel, A van den Berg, N Rüther, X Huang, M Wang, D de Jong, ... haematologica 97 (4), 572, 2012 | 51 | 2012 |
| Impact of etoposide and ASCT on survival among patients aged< 65 years with stage II to IV PTCL: a population-based cohort study M Brink, FO Meeuwes, MWM van der Poel, MJ Kersten, M Wondergem, ... Blood, The Journal of the American Society of Hematology 140 (9), 1009-1019, 2022 | 42 | 2022 |
| Combining brentuximab vedotin with DHAP as salvage treatment in relapsed/refractory Hodgkin lymphoma: the phase II HOVON/LLPC transplant BRaVE study A Hagenbeek, JM Zijlstra, WJ Plattel, F Morschhauser, PJ Lugtenburg, ... Blood 132, 2923, 2018 | 33 | 2018 |
| Insulin-like growth factor 1 receptor is a prognostic factor in classical Hodgkin lymphoma Z Liang, A Diepstra, C Xu, G van Imhoff, W Plattel, A Van Den Berg, ... PLoS One 9 (1), e87474, 2014 | 32 | 2014 |
| Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin's lymphoma WJ Plattel, HC Kluin-Nelemans, GH De Bock, GW Van Imhoff Bone marrow transplantation 46 (6), 827-834, 2011 | 20 | 2011 |
| Primary therapy and relative survival in classical Hodgkin lymphoma: A nationwide population-based study in the Netherlands, 1989–2017 J Driessen, O Visser, JM Zijlstra, PJ Lugtenburg, WJ Plattel, MJ Kersten, ... Leukemia 35 (2), 494-505, 2021 | 19 | 2021 |
| Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population‐based study during 1990–2015 AMJ Reedijk, EAM Zijtregtop, JWW Coebergh, FAG Meyer‐Wentrup, ... British journal of haematology 189 (6), 1093-1106, 2020 | 19 | 2020 |
| Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study M Brink, XU Kahle, JSP Vermaat, JM Zijlstra, M Chamuleau, MJ Kersten, ... Blood advances 5 (15), 2958-2964, 2021 | 18 | 2021 |
| Interim thymus and activation regulated chemokine versus interim 18F‐fluorodeoxyglucose positron‐emission tomography in classical Hodgkin lymphoma … WJ Plattel, L Visser, A Diepstra, AWJM Glaudemans, M Nijland, ... British Journal of Haematology 190 (1), 40-44, 2020 | 18 | 2020 |
| Long-term follow-up of the response-adapted intergroup EORTC/LYSA/FIL H10 trial for localized Hodgkin lymphoma M Federico, C Fortpied, Y Stepanishyna, M Gotti, R Van Der Maazen, ... Journal of Clinical Oncology 42 (1), 19-25, 2024 | 14 | 2024 |
| Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma J Veldman, ZND Alsada, A van den Berg, WJ Plattel, A Diepstra, L Visser British Journal of Haematology 193 (3), 506-514, 2021 | 14 | 2021 |
| Molecular imaging in lymphoma beyond 18F-FDG-PET: understanding the biology and its implications for diagnostics and therapy XU Kahle, FMM de Jesus, AWJM Glaudemans, MN Lub-de Hooge, ... The Lancet Haematology 7 (6), e479-e489, 2020 | 13 | 2020 |
| Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis WJ Plattel, A Bergamasco, F Trinchese, F Gavini, N Bent-Ennakhil, ... Leukemia & lymphoma 62 (14), 3320-3332, 2021 | 12 | 2021 |
| Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP J Driessen, MJ Kersten, L Visser, A van den Berg, SH Tonino, JM Zijlstra, ... Leukemia 36 (12), 2853-2862, 2022 | 11 | 2022 |
| Efficacy and safety of nivolumab combined with daratumumab with or without low-dose cyclophosphamide in relapsed/refractory multiple myeloma; interim analysis of the phase 2 … CPM Verkleij, MC Minnema, O de Weerdt, PWC Bosman, KA Frerichs, ... Blood 134, 1879, 2019 | 11 | 2019 |
| Low mutational burden of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in patients with primary Sjogren’s syndrome JAA Bult, JR Plaça, EA Haacke, MM Terpstra, GM Verstappen, ... Cancers 14 (4), 1010, 2022 | 9 | 2022 |
